Friday, April 15, 2016

BRIEF-Newlink Genetics receives $2.8 mln award from DTRA to develop a multivalent filovirus ...

Co and Merck continuing efforts for development of recombinant vesicular stomatitis virus-ebola zaire (RVSV-zebov) vaccine Source text for Eikon: … Full Article http://j.gs/5sTq

Click here to read full article
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)